Eszopiclone + Placebo
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea
Trial Timeline
Jan 1, 2009 โ May 1, 2010
NCT ID
NCT01102270About Eszopiclone + Placebo
Eszopiclone + Placebo is a phase 1 stage product being developed by Sumitomo Pharma for Obstructive Sleep Apnea. The current trial status is completed. This product is registered under clinical trial identifier NCT01102270. Target conditions include Obstructive Sleep Apnea.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01102270 | Phase 1 | Completed |
| NCT00645944 | Pre-clinical | Completed |
| NCT00826111 | Approved | Completed |
| NCT00414037 | Approved | Terminated |
| NCT00386334 | Approved | Completed |
| NCT00833547 | Pre-clinical | Completed |
| NCT00392041 | Approved | Completed |
| NCT00365976 | Approved | Completed |
| NCT00555750 | Pre-clinical | Completed |
| NCT00374192 | Pre-clinical | Completed |
| NCT00368056 | Phase 3 | Completed |
| NCT00368160 | Phase 1 | Completed |
| NCT00367965 | Phase 3 | Completed |
| NCT00366093 | Phase 3 | Completed |
| NCT00352144 | Phase 3 | Completed |
| NCT00685269 | Phase 2 | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea